Coronary arterial microvascular disease
Conditions
Interventions
Test group:After the meal, orally Guanxinning tablet, 4 tablets at a time, 3 times a day.
Control group:After the meal, orally Guanxinning placebo, 4 tablets at a time, 3 times a day.
Sponsors
Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) 18-80 years old; (2) Individuals exhibiting symptoms of exertional or resting angina; (3) Patients with ischemic electrocardiographic changes during angina attacks, or positive results in plate exercise tests, or transient and reversible local wall motion abnormalities or perfusion defects during stress single photon emission computed tomography (SPECT)/PET/cardiac magnetic resonance imaging (MRI)/echocardiography examinations, or other evidence of myocardial ischemia; (4) MFR<2.0 and/or MPRI<2.0 for cardiac magnetic resonance imaging (CMR); (5)Voluntarily participate in this study and sign an informed consent form. If the subject does not have the ability to read the informed consent form (such as illiterate subjects), a witness must witness the informed process and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Subcardiac coronary artery stenosis = 50%; (2) Thrombotic coronary artery disease; (3) Acute coronary syndrome (within 1 year) or within 12 months after percutaneous coronary intervention with complete revascularization; (4) Severe heart failure (EF3 times the upper limit of normal); (15) Renal insufficiency (eGFR<30ml/min/1.73m2); (16) Acute exacerbation or worsening of chronic diseases; (17) Expected survival period<1 year; (18) Vulnerable groups, including individuals with mental illness, cognitive impairment, critically ill patients, minors, pregnant women, etc. (19) Patients who have participated in other clinical trials within the past month. (20) Researchers believe that there are patients with other factors that are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial blood flow reserve;Myocardial perfusion reserve index;Hemoglobin; | — |
Secondary
| Measure | Time frame |
|---|---|
| High density lipoprotein;Low density lipoprotein;Total cholesterol;Triglyceride;Alanine aminotransferase;Aspartate transaminase;Alkaline phosphatase;Gamma glutamyltransferase;Total bilirubin ;Direct bilirubin;Serum creatinine;Glomerular filtration rate;Urea nitrogen;Lipoprotein A;Glycosylated hemoglobin;Homocysteine;C-reactive protein;Activated partial thromboplastin time;Prothrombin time;International standardized ratio;D-dimer;Natriuretic peptide;Troponin I;Red blood cell;White blood cell;Platelet;Bld ;Urinary white blood cells;Urine protein;Urinary ketone bodies;Urobilinogen;Urine pregnancy test;Fecal occult blood;Fecal white blood cells;Serum untargeted metabolomics;Seattle Angina Questionnaire;Electrocardiogram;Cardiac ultrasound;Incidence of major adverse cardiovascular events (MACE); | — |
Countries
China
Contacts
Public ContactHuang he
Run Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed